// App-Quantinova.ai

1121M-09 : INTERLEUKIN-6 AND THE RISK OF ADVERSE OUTCOMES IN PATIENTS AFTER AN ACUTE CORONARY SYNDROME: OBSERVATIONS FROM THE SOLID-TIMI 52 TRIAL

Researchers

Presenter

  • Christina Fanola

Principal Investigators

  • David Morrow

  • Christopher Cannon

  • Petr Jarolim

  • Mary Ann Lukas

  • Erica Goodrich

  • Eugene Braunwald

  • Michelle -Donoghue

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Stroke

Biomarkers

  • Enzyme lipoprotein-associated phospholipase A2

  • High sensitivity C-reactive protein

  • Interleukin 6

Drug/Treatment

  • ILS-969

  • Darapladib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved